Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients

针对SARS-CoV-2刺突蛋白、膜蛋白和核衣壳蛋白的强效T细胞反应与重症COVID-19患者的康复无关

阅读:1
作者:Constantin J Thieme ,Moritz Anft ,Krystallenia Paniskaki ,Arturo Blazquez-Navarro ,Adrian Doevelaar ,Felix S Seibert ,Bodo Hoelzer ,Margarethe Justine Konik ,Marc Moritz Berger ,Thorsten Brenner ,Clemens Tempfer ,Carsten Watzl ,Toni L Meister ,Stephanie Pfaender ,Eike Steinmann ,Sebastian Dolff ,Ulf Dittmer ,Timm H Westhoff ,Oliver Witzke ,Ulrik Stervbo ,Toralf Roch ,Nina Babel

Abstract

T cell immunity toward SARS-CoV-2 spike (S-), membrane (M-), and nucleocapsid (N-) proteins may define COVID-19 severity. Therefore, we compare the SARS-CoV-2-reactive T cell responses in moderate, severe, and critical COVID-19 patients and unexposed donors. Overlapping peptide pools of all three proteins induce SARS-CoV-2-reactive T cell response with dominance of CD4+ over CD8+ T cells and demonstrate interindividual immunity against the three proteins. M-protein induces the highest frequencies of CD4+ T cells, suggesting its relevance for diagnosis and vaccination. The T cell response of critical COVID-19 patients is robust and comparable or even superior to non-critical patients. Virus clearance and COVID-19 survival are not associated with either SARS-CoV-2 T cell kinetics or magnitude of T cell responses, respectively. Thus, our data do not support the hypothesis of insufficient SARS-CoV-2-reactive immunity in critical COVID-19. Conversely, it indicates that activation of differentiated memory effector T cells could cause hyperreactivity and immunopathogenesis in critical patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。